Introduction
============

Renal cell carcinoma (RCC) accounts for nearly 85% of primary renal carcinomas, and in the United States, approximately 63,000 new cases and nearly 14,000 deaths occur each year ([@ref-4]). The most common pathological type of RCC is clear cell RCC (ccRCC), which accounts for approximately 70--75% of cases ([@ref-19]). However, 30% of patients with ccRCC are diagnosed with advanced cancer ([@ref-6]). The optimal treatment for localized ccRCC is radical resection, but the therapies available for advanced cancer with metastasis are not very effective. Currently, targeted therapy has become a promising strategy. Therefore, the identification of hub genes associated with ccRCC is important for targeted therapy.

Runt-related transcription factor 1 (RUNX1) is widely considered the master regulator of haematopoiesis that mediates endothelial-to-haematopoietic transition (EHT) and the homeostasis of haematopoietic stem and progenitor cells (HSPCs) ([@ref-24]; [@ref-25]; [@ref-1]). The results of increasing studies imply that RUNX1 has contrasting effects of promoting or suppressing tumorigenesis in various malignancies. For example, upregulation of RUNX1 led to the increased expression of SOS1 and phosphorylation of ErbB2/HER2, subsequently promoting the proliferation of gastric cancer cells ([@ref-12]). In the ER+ subtype of breast cancer, RUNX1 has been implicated as a tumour suppressor through the stabilization of Axis inhibition protein 1 (AXIN1) expression, but high RUNX1 expression correlates with poor prognosis in triple-negative breast cancers ([@ref-10]; [@ref-2]). Additionally, loss of RUNX1 resulted in enhanced proliferation, migration, and invasion in lung cancer ([@ref-17]). Recently, the literature in ccRCC reported the upregulation of RUNX1- RUNX1 partner transcriptional co-repressor 1 (RUNX1-RUNX1T1) gene signatures, the fusion transcript between the RUNX1 gene and the RUNX1T1 locus because of t(8;21)(q22;q22) ([@ref-11]), which was revealed by RNA sequencing ([@ref-23]). However, the relationship between RUNX1 and the prognosis of ccRCC is unknown.

Therefore, we assessed RUNX1 expression in ccRCC and evaluated the correlation between RUNX1 expression and the prognosis of ccRCC using the public dataset from The Cancer Genome Atlas (TCGA). GSEA was performed to explore the mechanisms of RUNX1 in ccRCC.

Materials and Methods
=====================

Basic patient information
-------------------------

The mRNA expression data and the corresponding clinical data of ccRCC patients were obtained from the official website of The Cancer Genome Atlas (TCGA). After excluding normal sample data, boxplots were used to analyse the relationship between RUNX1 expression and various clinical variables. Ultimately, we included 537 ccRCC patients with RUNX1 mRNA expression data and clinical data ([Table 1](#table-1){ref-type="table"}).
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###### Characteristics of clear cell renal cell carcinoma patients in the TCGA database.

![](peerj-07-7854-g004)

  Clinical characteristics                                            Total (*n* = 537)   \%
  -------------------------------------------------------- ---------- ------------------- ------
  Age at diagnosis (years)                                            61 (26--90)         
  Gender                                                   Female     191                 35.6
  Male                                                     346        64.4                
  Histological grade                                       I          14                  2.6
  II                                                       230        43.5                
  III                                                      207        39.2                
  IV                                                       78         14.7                
  Stage                                                    I          269                 50.3
                                                           II         57                  10.7
                                                           III        125                 23.4
                                                           IV         83                  15.6
  Tissue infiltration[^a^](#table-1fn1){ref-type="fn"}     Negative   344                 64.1
                                                           Positive   193                 35.9
  Lymph node metastasis[^b^](#table-1fn2){ref-type="fn"}   Negative   240                 93.3
                                                           Positive   17                  6.7
  Distant metastasis[^c^](#table-1fn3){ref-type="fn"}      Negative   426                 84.3
                                                           Positive   79                  15.7

**Notes.**

Positive indicates tissue infiltration and negative indicates no tissue infiltration.

Positive indicates lymph node metastasis and negative indicates no lymph node metastasis.

Positive indicates distant metastasis and negative indicates no distant metastasis.

Gene set enrichment analysis (GSEA)
-----------------------------------

GSEA was utilized to explore the mechanisms of RUNX1 in ccRCC. In this study, the "c2.cp.kegg.v6.2.symbols.gmt" gene sets from the Molecular Signatures Database (MSigDB) were analysed using GSEA 3.0 software. To obtain normalized enrichment scores (NESs), the nominal *p*-value and false discovery rate (FDR) *q*-value were determined, the number of gene set permutations for each analysis was set at 1,000, and the phenotype label was the expression level of RUNX1. Gene sets with a nominal *p*-value of \<0.05 and an FDR *q*-value of \<0.25 were considered significantly enriched gene sets.

Statistical analysis
--------------------

The median value of RUNX1 expression was considered as the cut-off value. The Wilcoxon signed-rank test was used to compare the expression of RUNX1 in ccRCC tissues with that in normal tissues. The Wilcoxon signed-rank test and logistic regression were utilized to investigate the relationship between clinicopathological factors and RUNX1. The correlation between RUNX1 expression and overall survival (OS) was estimated using Kaplan--Meier survival curves. Univariate Cox regression analysis was used to calculate the association of clinicopathological characteristics and RUNX1 expression with OS, and multivariate Cox analysis was carried out for further analysis. All statistical analyses were performed using R 3.5.3 software ([@ref-16]).

Results
=======

Patient characteristics
-----------------------

A total of 537 primary tumours with both gene expression and clinical data were downloaded from TCGA ccRCC data in May 2019. In our study cohort, the median age was 63 years (range, 26--90 years). Histological grades I, II, III, and IV accounted for 2.6%, 43.5%, 39.2%, and 14.7% of the cases, respectively. Stages I, II, III and IV accounted for 50.3%, 10.7%, 23.4% and 15.6% of the cases, respectively. A total of 193 of the 537 (35.9%) cases had tissue infiltration. A total of 17 of 257 (6.7%) cases had lymph node metastasis, and 79 of 505 (6.7%) cases had distant metastasis ([Table 1](#table-1){ref-type="table"}).

RUNX1 was highly expressed in ccRCC tissues
-------------------------------------------

We compared the expression of RUNX1 in 539 ccRCC tissues and 72 normal tissues using the Wilcoxon signed-rank test. The expression of RUNX1 in ccRCC tissues was significantly higher than that in normal tissues (*p* \< 0.001) ([Fig. 1A](#fig-1){ref-type="fig"}). In addition, RUNX1 was also obviously overexpressed in the ccRCC tissues relative to its expression in the 72 paired normal tissues (*p* \< 0.001) ([Fig. 1B](#fig-1){ref-type="fig"}).

![Comparison of RUNX1 expression between ccRCC tissues and normal tissues.\
The Wilcoxon signed-rank test was used to compare the mRNA expression of RUNX1 in ccRCC tissues and normal tissues obtained from the TCGA database. (A) The expression of RUNX1 in ccRCC tissues (*n* = 539) was significantly higher than that in normal tissues (*n* = 72). (B) Compared with 72 paired normal tissues, ccRCC tissues exhibited obvious overexpression of RUNX1. RUNX1, Runt-related transcription factor 1; ccRCC, clear cell renal cell carcinoma; TCGA, The Cancer Genome Atlas ; \*, *p* \< 0.05 ; \*\*, *p* \< 0.01; \*\*\*, *p* \< 0.001.](peerj-07-7854-g001){#fig-1}

The expression of RUNX1 and its association with clinicopathological variables
------------------------------------------------------------------------------

We used the Wilcoxon signed-rank test to analyse 537 ccRCC samples from the TCGA database with both RUNX1 expression data and clinical data. The median value of RUNX1 expression was considered as the cut-off value. As shown in [Figs. 2A](#fig-2){ref-type="fig"}--[2E](#fig-2){ref-type="fig"}, high expression of RUNX1 was significantly associated with gender (*p* = 0.003), clinical stage (*p* \< 0.001), tissue infiltration (*p* \< 0.001), lymph node metastasis (*p* = 0.037) and histological grade (*p* \< 0.001). The logistic regression analysis results showed that high RUNX1 expression was significantly correlated with gender (odds ratio \[OR\] = 1.71 for male vs. female, *p* = 0.004), histologic grade (OR = 11.61 for grade IV vs. I, *p* \< 0.001), stage (OR = 1.55 for stage III/IV vs. I/II, *p* = 0.014) and tissue infiltration (OR = 1.54 for positive vs. negative, *p* = 0.018) ([Table 2](#table-2){ref-type="table"}).

![The expression of RUNX1 and its association with clinicopathologic variables.\
The median value of RUNX1 expression was considered as the cut-off value. The Wilcoxon signed-rank test was utilized to investigate the relationship between clinicopathological factors and the expression of RUNX1 in 537 ccRCC tissues. The correlation between RUNX1 expression and overall survival (OS) was estimated using Kaplan--Meier survival curves. (A) Gender, (B) clinical stage, (C) tissue infiltration, (D) lymph node metastasis, (E) histological grade and (F) Kaplan--Meier survival curves showed that the prognosis of patients with ccRCC with high RUNX1 expression was worse than that of patients with ccRCC with low RUNX1 expression. In (C), positive indicates tissue infiltration and negative indicates no tissue infiltration. In (D), positive indicates lymph node metastasis and negative indicates no lymph node metastasis. RUNX1, Runt-related transcription factor 1; ccRCC, clear cell renal cell carcinoma; \*, *p* \< 0.05; \*\*, *p* \< 0.01; \*\*\*, *p* \< 0.001.](peerj-07-7854-g002){#fig-2}
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###### Association of RUNX1 expression[^a^](#table-2fn1){ref-type="fn"} with clinicopathological characteristics (logistic regression analysis).
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  Clinical characteristics                                                         Total (N)   Odds ratio for RUNX1 expression   *p*-value
  -------------------------------------------------------------------------------- ----------- --------------------------------- -----------
  Age (continuous)                                                                 537         0.99 (0.98--1.01)                 0.659
  Gender (male vs. female)                                                         537         1.71 (1.19--2.45)                 0.004
  Grade (IV vs. I)                                                                 92          11.61 (3.22--55.67)               0.000
  Stage (III/IV vs. I/II)                                                          527         1.55 (1.09--2.21)                 0.014
  Distant metastasis (positive vs. negative)[^b^](#table-2fn2){ref-type="fn"}      505         1.36 (0.84--2.21)                 0.219
  Tissue infiltration (positive vs. negative)[^c^](#table-2fn3){ref-type="fn"}     537         1.54 (1.07--2.19)                 0.018
  Lymph node metastasis (positive vs. negative)[^d^](#table-2fn4){ref-type="fn"}   257         1.73 (0.63--5.24)                 0.299

**Notes.**

Categorical dependent variable, greater or less than the median expression level.

Positive indicates distant metastasis and negative indicates no distant metastasis.

Positive indicates tissue infiltration and negative indicates no tissue infiltration.

Positive indicates lymph node metastasis and negative indicates no lymph node metastasis.

Survival outcomes and Cox regression analyses
---------------------------------------------

Kaplan--Meier survival curves revealed that the prognosis of patients with ccRCC with high RUNX1 expression was worse than that of patients with ccRCC with low RUNX1 expression (*p* \< 0.001) ([Fig. 2F](#fig-2){ref-type="fig"}). The univariate Cox regression analysis results showed that high RUNX1 expression was strongly correlated with poor prognosis (hazard ratio \[HR\] = 1.60, 95% confidence interval CI \[1.31--1.97\], *p* \< 0.001; [Table 3A](#table-3){ref-type="table"}). Other clinical variables, such as age, grade, stage, distant metastasis, tissue infiltration and lymph node metastasis, were found to have an impact on OS (all *p* values \<0.05). Moreover, in multivariate analysis, high expression of RUNX1 (HR =1.50, 95% CI \[1.20--1.87\], *p* \< 0.001), age (HR =1.03, 95% CI \[1.01--1.05\], *p* = 0.002) and distant metastasis (HR =2.42, 95% CI \[1.14--5.16\], *p* = 0.022) still implied a poor prognosis ([Table 3A](#table-3){ref-type="table"}). These results indicate that the expression of RUNX1 is an independent factor and that increased RUNX1 levels are associated with poor OS.
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###### Association with overall survival and clinicopathological characteristics in patients from the TCGA database using Cox regression.

\(A\) Univariate Cox regression (B) Multivariate Cox regression.
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  Clinicopathological variables                                                    Hazard ratio (95% CI)   *p*-value
  -------------------------------------------------------------------------------- ----------------------- -----------
  (**A**)                                                                                                  
  Age (continuous)                                                                 1.02 (1.00--1.04)       0.012
  Gender (male vs. female)                                                         1.01 (0.67--1.54)       0.951
  RUNX1 expression (high vs. low)                                                  1.60 (1.31--1.97)       0.000
  Grade                                                                            2.24 (1.68--2.99)       0.000
  Stage                                                                            1.86 (1.54--2.25)       0.000
  Distant metastasis (positive vs. negative)[^a^](#table-3fn1){ref-type="fn"}      4.07 (2.63--6.30)       0.000
  Tissue infiltration (positive vs. negative)[^b^](#table-3fn2){ref-type="fn"}     3.31 (2.17--5.06)       0.000
  Lymph node metastasis (positive vs. negative)[^c^](#table-3fn3){ref-type="fn"}   2.93 (1.52--5.67)       0.001
  (**B**)                                                                                                  
  Age (continuous)                                                                 1.03 (1.01--1.05)       0.002
  RUNX1 expression (high vs. low)                                                  1.50 (1.20--1.87)       0.000
  Distant metastasis (positive vs. negative)                                       2.42 (1.14--5.16)       0.022

**Notes.**

Positive indicates distant metastasis and negative indicates no distant metastasis.

Positive indicates tissue infiltration and negative indicates no tissue infiltration.

Positive indicates lymph node metastasis and negative indicates no lymph node metastasis.

GSEA
----

GSEA was conducted to identify the differentially activated signalling pathways in the high RUNX1 expression ccRCC data sets. The results shown in [Table 4](#table-4){ref-type="table"} and [Fig. 3](#fig-3){ref-type="fig"} revealed the most significant signalling pathways enriched in the RUNX1 high-expression phenotype.
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###### Gene sets enriched in the high-expression phenotype.
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  Gene set name                               NES     NOM *p*-val   FDR *q*-val
  ------------------------------------------- ------- ------------- -------------
  KEGG_APOPTOSIS                              1.970   0.002         0.005
  KEGG_B\_CELL_RECEPTOR_SIGNALING_PATHWAY     2.069   0.000         0.003
  KEGG_CALCIUM_SIGNALING_PATHWAY              2.021   0.000         0.004
  KEGG_CHEMOKINE_SIGNALING_PATHWAY            2.145   0.000         0.001
  KEGG_JAK_STAT_SIGNALING_PATHWAY             2.242   0.000         0.000
  KEGG_MAPK_SIGNALING_PATHWAY                 1.997   0.002         0.004
  KEGG_P53_SIGNALING_PATHWAY                  2.022   0.002         0.004
  KEGG_PATHWAYS_IN_CANCER                     2.075   0.004         0.003
  KEGG_T\_CELL_RECEPTOR_SIGNALING_PATHWAY     1.973   0.002         0.005
  KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY   2.007   0.002         0.004
  KEGG_VEGF_SIGNALING_PATHWAY                 1.966   0.002         0.005
  KEGG_WNT_SIGNALING_PATHWAY                  2.009   0.004         0.004

**Notes.**

NESnormalized enrichment scoreNOMnominal;FDRfalse discovery rate

Gene sets with NOM *p*-val \<0.05 and FDR *q*-val \<0.25 were considered significant.

![GSEA.\
GSEA was conducted to identify the differentially activated signalling pathways in the high RUNX1 expression ccRCC data sets. GESA showed that the apoptosis, the B cell receptor signalling pathway, the Calcium signalling pathway, the chemokine signalling pathway, the JAK/STAT signalling pathway, the MAPK signalling pathway, the p53 signalling pathway, pathways in cancer, the T cell receptor signalling pathway, the Toll-like receptor signalling pathway, the VEGF signalling pathway, and the Wnt signalling pathway were significantly enriched in the RUNX1 high-expression phenotype. GSEA, gene set enrichment analysis; RUNX1, Runt-related transcription factor 1; ccRCC, clear cell renal cell carcinoma; NOM *p*-val, nominal *p*-value ; FDR *q*-val, false discovery rate *q*-value.](peerj-07-7854-g003){#fig-3}

Discussion
==========

RUNX1, located on chromosome 21q22.3, consists of 12 exons with two distinct promoters and modulates the transcription of its target genes by affecting the DNA binding capacity ([@ref-3]; [@ref-12]; [@ref-8]). Researchers have demonstrated differential expression of RUNX1 in several cancers, and deregulation of RUNX1 correlates with tumour progression, which could ultimately lead to its dual role. For example, the expression of RUNX1 in hepatocellular carcinoma tissues is much lower than that in adjacent normal tissues and adjacent cirrhotic tissues ([@ref-13]). In addition, RUNX1 is overexpressed in non-small cell lung cancer (NSCLC) and promotes the invasion of NSCLC cells ([@ref-22]). RUNX1 was also confirmed to be upregulated in endometrial cancer and related to myometrial invasion ([@ref-15]). Knockdown of RUNX1 inhibited proliferation and apoptosis induced by Leucine-rich-alpha-2-glycoprotein 1 (LRG1) in colorectal cancer cells ([@ref-26]). RUNX1 has been shown to be androgen-dependent, and loss of RUNX1 may contribute to prostate cancer progression ([@ref-21]). Additionally, RUNX1 suppress the growth of several breast cancer cell lines through the repression of cancer stem cell activity and inhibition of zinc finger E-Box binding protein 1 (ZEB1) expression ([@ref-5]). However, the effect of RUNX1 expression on the prognosis of RCC, which is the focus of the current study, remains unclear.

Here, we confirmed that the RUNX1 high-expression phenotype was closely correlated with gender, high histological grade, advanced clinical stage, tissue infiltration and poor prognosis. GSEA was performed to further investigate the biological functions of RUNX1 in ccRCC. GESA is one of the most commonly used methods for pathway analysis in tumours. The results of GESA are based on gene sets rather than a single gene, making these results more reliable and flexible than those obtained using traditional methods ([@ref-20]). However, the approach of GESA, functional class scoring (FCS), has several limitations. FCS analyses each pathway independently and treats differently significant genes equally, which may overlook the biological significance of genes within these pathways and their complex interactions with each other ([@ref-7]). Additionally, it is difficult to set the appropriate threshold for determining gene sets for pathways with insufficient annotation information, which may lead to the loss of some less significant but still critical genes, resulting in reduced detection sensitivity. GESA showed that apoptosis, the B cell receptor signalling pathway, the calcium signalling pathway, the chemokine signalling pathway, the JAK/STAT signalling pathway, the MAPK signalling pathway, the p53 signalling pathway, pathways in cancer, the T cell receptor signalling pathway, the Toll like receptor signalling pathway, the VEGF signalling pathway, and the Wnt signalling pathway were significantly enriched in the RUNX1 high-expression phenotype. Some of these pathways have been reported in the literature related to other cancers. The distal P1-Runx1 promoter may be important in the onset or progression of leukaemia via Wnt/beta-catenin signalling ([@ref-9]). RUNX1 gene silencing induces p53-promoted core binding factor-beta (CBFB) expression, and upregulated CBFB stabilizes RUNX1 expression in acute myeloid leukaemia cells, resulting in a compensatory RUNX1-p53-CBFB feedback loop ([@ref-14]). Moreover, IL-1*β* induces RUNX1 expression through the MAPK signalling pathway and promotes migration, invasion, and angiogenesis in glioblastoma ([@ref-18]). However, the association of RUNX1 with the ccRCC signalling pathways has not been studied. Our findings suggest that RUNX1 can be used as a novel biomarker for predicting poor prognosis and as a therapeutic target in ccRCC, but the underlying mechanisms need to be further elucidated.

Although the current study elaborated on the role of RUNX1 in ccRCC, it still has some limitations. First, the number of tumour tissues in the TCGA database was significantly higher than the number of normal tissues used as a control. Second, specific details, such as the use of drugs, surgical treatment and surgical details, are lacking, and these factors are important for patient prognosis. Finally, the protein levels and direct mechanisms of RUNX1 in ccRCC could not be clearly assessed from the TCGA database. Therefore, further studies on RUNX1 in ccRCC are needed.

Conclusions
===========

The expression of RUNX1 may be associated with poor survival in ccRCC, and the apoptosis, the B cell receptor signalling pathway, the calcium signalling pathway, the chemokine signalling pathway, the JAK/STAT signalling pathway, the MAPK signalling pathway, the p53 signalling pathway, pathways in cancer, the T cell receptor signalling pathway, the Toll-like receptor signalling pathway, the VEGF signalling pathway, and the Wnt signalling pathway may be significantly correlated with RUNX1 expression in ccRCC. The biological role of RUNX1 in ccRCC should be further assessed in future studies.
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